Radiopharmaceutical · Kills target cells, directed at HER2 (ERBB2) · developed by Radiopharm Theranostics
177Lu-RAD202 is a lutetium-177 radiopharmaceutical given at treatment doses. It is studied in advanced solid tumors with HER2 gene mutation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06824155 | Early Phase 1 | HER2 Gene Mutation | Recruiting | RADX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsHER2 Gene Mutation
Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.
See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RADX catalysts and pipeline →